Autonomic Dysfunction Presenting as Postural Orthostatic Tachycardia Syndrome in Patients with Multiple Sclerosis by Kanjwal, Khalil et al.
Int. J. Med. Sci. 2010, 7 
 
 
http://www.medsci.org 
62
I In nt te er rn na at ti io on na al l   J Jo ou ur rn na al l   o of f   M Me ed di ic ca al l   S Sc ci ie en nc ce es s   
2010; 7(2):62-67 
© Ivyspring International Publisher. All rights reserved 
Research Paper 
Autonomic Dysfunction Presenting as Postural Orthostatic Tachycardia 
Syndrome in Patients with Multiple Sclerosis 
Khalil Kanjwal, Beverly Karabin, Yousuf Kanjwal, Blair P Grubb 
 
Department of Medicine, Division of Cardiology Section of Electrophysiology, The University of Toledo, Toledo, OH 43614, 
USA.  

 Corresponding author: Blair P Grubb, MD, Director Electrophysiology Services, Division of Cardiology, Department of 
Medicine, Health Sciences Campus, University of Toledo Medical Center, Mail Stop 1118, 3000 Arlington Ave., Toledo OH 
43614. USA. Phone 419-3833778; Fax: 419-383-3041. 
Received: 2010.03.01; Accepted: 2010.03.10; Published: 2010.03.11 
Abstract 
Background: Autonomic dysfunction is common in patients suffering from multiple sclero-
sis (MS) and orthostatic dizziness occurs in almost 50% of these patients. However, there 
have been no reports on postural orthostatic tachycardia syndrome (POTS) in patients suf-
fering from MS. 
Methods: The patients were included for analysis in this study if they had POTS with either 
a prior history of MS or having developed MS while being followed for POTS. Postural or-
thostatic tachycardia (POTS) is defined as symptoms of orthostatic intolerance(>6months) 
accompanied by a heart rate increase of at least 30 beats/min (or a rate that exceeds 120 
beats/min) that occurs in the first 10 minutes of upright posture or head up tilt test (HUTT) 
occurring in the absence of other chronic debilitating disorders. We identified nine patients 
with POTS who were suffering from MS as well. Each of these patients had been referred 
from various other centers for second opinions. 
Results: The mean age at the time of diagnosis of POTS was 49±9 years and eight of the 9 
patients were women. Five patients (55%) had hyperlipidemia, 3 (33%) migraine and 2 (22%) 
patients had coronary artery disease and diabetes each. Fatigue and palpitations (on assuming 
upright posture) were the most common finding in our patients (9/9). All patients also had 
orthostatic dizziness. Syncope was seen in 5/9(55%) of patients. Four patients (44%), who did 
not have clear syncope, were having episodes of near syncope. The presence of POTS in our 
study population resulted in substantial limitation of daily activities. Following recognition 
and treatment of POTS, 6/9(66%), patients were able to resume daily activities of living. 
Their symptoms (especially fatigue and orthostatic intolerance) improved. The frequency 
and severity of syncope also improved. Three (33%) patients failed to show a good response 
to treatment. 
Conclusion: Patients suffering from MS may manifest autonomic dysfunction by developing 
POTS. Early recognition and proper management may help improve the symptoms of POTS. 
Key words: Multiple sclerosis, Postural tachycardia syndrome, syncope, dizziness, fatigue. 
Introduction 
Multiple sclerosis (MS) is a chronic demyelinat-
ing inflammatory disorder, presumed to be of auto-
immune etiology. Autonomic dysfunction (AD) is 
commonly seen in patients with MS. The most com-
mon manifestations of the AD in patients with MS 
include bladder dysfunction, sleep disturabances, Int. J. Med. Sci. 2010, 7 
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sweating, gastrointestinal and cardiovascular distur-
bances. Another common symptom seen in patients of 
MS is fatigue. Orthostatic dizziness (OD) has been 
reported to occur in up to 50% of MS patients (1-4). 
Autonomic dysfunction has an important impact on 
the disability that patients with MS experience and 
can substantially restrict the activities of daily living 
in these individuals.  
Autonomic dysfunction in patients with MS is 
felt to occur because of involvement of several critical 
pathways of autonomic nervous system, including the 
brain stem, spinal cord, hypothalamus and cerebral 
cortex. Demyelinating plaques may disrupt reflex 
pathways in the insular, cingulated and ventromedial 
prefrontal cortices, central nucleus of the amygdala, 
paraventricular hypothalamus and the medulla. In 
addition there can be interference with the descending 
autonomic nervous system pathways during their 
course in the brainstem or spinal cord (6). Although 
orthostatic dizziness has been commonly seen in pa-
tients of MS, to date there have been no studies or 
reports on the occurrence of postural orthostatic 
tachycardia syndrome (POTS) in patients with MS. 
We report on a series of nine MS patients with POTS. 
 
Methods 
The study was a retrospective descriptive analy-
sis of the patients followed up at the University of 
Toledo Autonomic Disorder Center. The study was 
approved by our Institutional Review Board. The data 
of these patients had been collected from1998-2008. 
Nine patients were identified that were included in 
the analysis. These patients were initially seen else-
where and were seen in our clinic for second opinions. 
All but two patients were diagnosed with multiple 
sclerosis. The diagnosis of MS was based on clinical 
history, neurological examination and supported by 
cerebrospinal fluid analysis and Magnetic Resonance 
Imaging of the brain in each case. Two patients with 
POTS, who were followed at our clinic, developed 
multiple sclerosis after being diagnosed with POTS. 
Criterion for diagnosis of POTS: The diagnosis of 
POTS was based on clinical history, clinical examina-
tion and a positive (POTS pattern) head up tilt test 
(HUTT). The HUTT criterion for diagnosing POTS 
was an absolute heart rate >120 bpm or an increase by 
> 30bpm within the first ten minutes of an upright tilt. 
We did not routinely evaluate catecholamine levels in 
any of these patients. 
A neurologist followed each of these patients 
and close contacts were maintained between our cen-
ter and the patients’ neurologist. The patients’ neu-
rological and autonomic center data (charts and/or 
physician letters) were then carefully reviewed for 
demographic characteristics, comorbid conditions, 
symptoms of MS, symptoms of POTS, medications 
and response to medication. The data obtained are 
presented as mean ± standard deviation or as per-
centages where applicable. 
Response to therapy  
Response to therapy was subjectively assessed in 
each patient. None of the patients underwent a repeat 
HUTT test for objective assessment of symptom re-
sponse to therapy. The therapy was considered suc-
cessful if it provided symptom relief. 
 
Results 
Nine patients with POTS who either had a prior 
h ist o ry o f M S o r d ev elo p ed M S w ere  iden t i fied  fo r  
inclusion in the study. The mean age at the time of 
diagnosis was 49±9 years and 8 of the 9 patients were 
women. All the patients were Caucasians. All patients 
were being followed by a neurologist who specialized 
in MS. The results are summarized in Table 1. 
Comorbidity 
Five patients (55%) had hyperlipidemia, 3 (33%) 
migraine and 2 (22%) patients had coronary artery 
disease and diabetes each. 
Symptoms of POTS 
Fatigue and palpitations (on assuming upright 
posture) were the most common finding in our pa-
tients (9/9). All patients also had orthostatic dizzi-
ness. Syncope was seen in 5/9(55%) of patients. Four 
patients (44%), who did not have frank syncope, were 
having episodes of near syncope. Each patient had 
experienced symptoms for greater than six months. 
Head up Tilt Test (HUTT): All nine patients un-
derwent HUTT. All patients demonstrated either an 
ab so l ut e h ea r t  rat e o f > 1 2 0b p m  o r an  in c re ase o f >  
30bpm within the first ten minutes of an upright tilt. 
All patients demonstrated symptoms of orthostatic 
intolerance similar to that reported during their 
spontaneous episodes. None of the patients had a 
resting heart rate > 100 bpm. We did not evaluate 
catecholamine levels in any of these patients. 
Symptoms of Multiple Sclerosis 
Visual disturbances in the form of episodic blur-
ring of vision were seen in 4/9(44%) patients. Sensory 
disturbances including numbness, tingling, pins and 
needles sensation in extremities were seen in 
4/9(44%) patients. Gait problems (leg and/or arm 
weakness) were also seen in 4/9(44%) patients. Sei-
zures were seen in two (22%) patients. Two (22%) Int. J. Med. Sci. 2010, 7 
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patients had recurrent bladder symptoms in form of 
incontinence and retention. Another two (22%) had 
been having excessive sweating. 
 
Table 1: Clinical characteristics of the patients of Multiple 
Sclerosis and orthostatic intolerance. 
Characteristics Values 
Age(years) 49±9 
Race (Caucasians %)  100 
Sex (Females)  8/9 (89%) 
  
Comorbid Condition   
Hyperlipidemia 5/9  (55%) 
Migraine 3/9  (33%) 
Coronary artery disease  2/9 (22%) 
Diabetes 2/9  (22%) 
  
Symptoms of POTS   
Fatigue 9/9  (77%) 
Dizziness/Near Syncope  9/9(100%) 
Palpitation 9/9(55%) 
Syncope 5/9(55%) 
Symptoms of Multiple Sclerosis   
Visual Disturbances(optic neuritis)  4/9(44%) 
Gait Problem/ Weakness  4/9 (44%) 
Sensory disturbances  4/9 (44%) 
Urinary Symptoms  2/9(22%) 
Seizures 2/9  (22%) 
  
Medications   
SSRI 7/9(77%) 
Pyridostigmine 6/9(66%) 
Midodrine 4/9  (45%) 
Betablockers 3/9(33%) 
Fludrocortisone 2/7(22%) 
Modefinil 1/9(11%) 
Combination 5/9(55%) 
  
Onset of POTS in relation to Multiple 
Sclerosis(MS) 
 
Followed MS  7/9(77%) 
Preceded MS   2/9(22%) 
  
Response of POTS symptoms to medical 
therapy 
 
Successful 6/9(66%) 
Failure 3/9(33%) 
Number of patients requiring Pacemaker  2/9(22%) 
 
Onset of POTS in relation to MS 
Two patients developed POTS prior to diagnosis 
of MS. One of these patient developed POTS three 
years, and another, one and a half years before the 
onset of MS. Seven (77%) patients’ developed POTS 
over a mean period of (22 months) from the diagnosis 
of the multiple sclerosis.  
Daily activities and lifestyle in our study patients 
Each of the patients reported a constant fear of 
experiencing syncope. This fear had greatly limited 
their daily activities to a point that they were scared of 
assuming an upright posture and had become home 
bound. One patient had a recurrent feeling of a sense 
of impending doom.  
Medications 
Treatment aimed at minimizing symptoms was 
initiated in each patient following the diagnosis of 
POTS. The majority of these patients were on selective 
serotonin reuptake inhibitors (venlafaxine and du-
loxetine) (7/9, 77%). Six (66%) patients were on pyri-
dostigmine, 4(44%) on midodrine, 3(33%) on 
beta-blockers (propranolol), 2 (22%) on fludrocorti-
sone and one (11%) on modafinil. Five (55%) patients 
were receiving a combination of one of these medica-
tions. 
Response to Medical therapy 
The therapeutic management approach for these 
patients was based on our previous experience with 
the management of patients with POTS. Initial ther-
apy consisted of an increase in salt and fluid intake as 
well as aerobic reconditioning with resistance training 
to increase lower extremity strength. Pharmacother-
apy was used alone or in combination in the following 
order: fludrocortisone 0.1mg po bid, midodrine 5-10 
mg po tid, propanolol10 mg po tid, pyrodostigmine 
60 mg po bid, serotonin reuptake inhibitor or modaf-
inil 100 mg po qam. Not every patient received every 
medication. Following recognition and treatment of 
POTS, 6/9(66%) patients were able to engage in daily 
activities of living. Fatigue and orthostatic intolerance 
were the symptoms which improved most. The fre-
quency and severity of syncope also improved sig-
nificantly. Three (33%) patients failed to demonstrate 
a good response to medical therapy and continued to 
experience recurrent syncope. Two out of these three 
patients had convulsive activity without prodrome 
during syncope. These two patients were further in-
vestigated by placement of an implantable loop re-
corder and were found to have periods of prolonged 
asystole during their episodes of syncope felt to be 
neurocardiogenic in nature. Thus these two patients 
had MS with POTS as well as episodes of neurocar-
diogenic syncope. Both of them received a dual 
chamber pacemaker. Following pacing one patient 
experienced complete elimination of syncope while 
the other experienced a significant reduction in fre-
quency and severity of her events. Another patient 
did not show a good response to therapy and contin-
ues to have episodes of orthostatic dizziness and 
syncope. Int. J. Med. Sci. 2010, 7 
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Discussion 
POTS is defined as an excessive increase in heart 
rate associated with symptoms of more than 6 
months’ duration (in the absence of other conditions 
that could mimic this such as dehydration and de-
conditioning). In POTS, the heart rate increases 30 
beats per minute (or exceeds 120 beats per minute) 
within the first 10 minutes of standing or HUTT. More 
complete descriptions of the diagnosis and manage-
ment of POTS are given elsewhere (7-11). Multiple 
sclerosis (MS) is an autoimmune inflammatory de-
myelinating disease of the central nervous system 
(CNS) that is a leading cause of disability in young 
adults.  
Autonomic dysfunction is commonly seen in 
patients with MS (1-5). In patients of MS, autonomic 
dysfunction (AD) has been thought to be related to 
involvement of reflex pathways in the brainstem (12).  
Both decreased heart rate variability and de-
creased blood pressure response in tilt table testing 
occur as a result of AD in patients with MS (12-16). On 
cardiovascular reflex testing it has been shown that 
both sympathetic as well as parasympathetic dys-
function can occur in patients with MS (12-16). Re-
duced heart rate variability and vasomotor dysfunc-
tion in MS appears to correlate with the degree of 
plaque burden seen on MRI in the midbrain areas, 
also with the presence of hemispherical lesions (17). 
Autonomic regulatory abnormalities are thought to 
occur due to involvement of central autonomic inter-
connections (18). In a study of carotid baroreflex in 
MS patients the baroreflex dysfunction involved both 
cardiovagal limb of the baroreflex as well the sym-
pathetic modulation of blood vessels (19). In addition, 
impaired sympathetic nervous system mediated 
vasomotor control may result in orthostatic intoler-
ance and dizziness that is seen in almost 50% of MS 
patients (20). Autonomic cardiovascular dysfunction 
may progress over time as was shown in a report by 
Nasseri et al. (21, 22). Sympathetic vasomotor dys-
function may also contribute to fatigue in patients 
with MS (23). As has been noticed previously the 
majority of our patients were females. Both POTS and 
MS occur more commonly in women of childbearing 
age. All of our patients were of Caucasian descent.  
Symptoms of POTS and MS 
The most common symptom in our study 
population was fatigue. Fatigue is a characteristic 
finding in MS, usually described as physical exhaus-
tion that is unrelated to the amount of activity per-
formed. Many patients complain of feeling exhausted 
on waking, even if they have slept soundly. Fatigue 
can also occur during the day but may be only par-
tially relieved by rest. In addition, there appears to be 
a correlation between fatigue and disrupted sleep in 
MS patients. In our patients, we were not able to ob-
tain any information about their sleep habits. Despite 
being a common symptom of MS there has been no 
correlation between fatigue and the overall severity of 
disease (24-26). All of our patients had orthostatic 
intolerance. Fifty percent patients of POTS have been 
reported to have orthostatic dizziness in various 
studies. Syncope which is uncommon in MS patients 
occurred in almost 5/9(55%) of patients in this study. 
Increase in cerebrovascular resistance occurring dur-
ing orthostatic stress can explain loss of consciousness 
in these patients (27). In two patients the episodes of 
syncope were associated with prolonged periods of 
asystole felt to be neurocardiogenic in origin. Postural 
orthostatic tachycardia with asystole has been re-
ported during HUTT testing (28). In addition to fa-
tigue our patients also presented with episodic visual 
disturbances (blurring of vision, optic neuritis), ex-
tremity weakness and sensory abnormalities like 
numbness and tingling. Seizures which occur usually 
in 2-3% (29) of MS patients were seen in 2/9 (22%) of 
patient in this selected cohort. This high incidence of 
seizure, syncope and asystole in this series might be 
due to the selection bias in this small group of pa-
tients. 
Management of POTS in patients with MS 
The pharmacological management of POTS in 
patients of MS was similar to that in patients without 
a history of MS. In our small group of patients, six 
patients showed a good response to a combination of 
medications (Table 1). Two patients who had recur-
rent episodes of abrupt onset syncope with convulsive 
activity were found to have periods of prolonged 
asystole on implantable loop recorder (ILR) monitor-
ing and subsequently received a pacemaker. In one of 
these patients, her episodes of syncope were elimi-
nated whereas in another, the episodes now have a 
prodrome and have decreased in severity and fre-
quency. Patients who have abrupt onset syncope with 
convulsive activity might have prolonged episodes of 
bradycardia or an asystole as a cause for their syncope 
(30, 31). 
Another patient continues to experience palpita-
tions and episodes of syncope and has failed multiple 
medications when used either alone or in combina-
tion. Interestingly two (22%) patients in our series had 
an onset of POTS prior to the diagnosis of MS while 
seven (77%) developed POTS over months to years 
following diagnosis of MS. It is difficult at this time to 
predict which POTS patients could develop MS, or 
which MS patients could develop POTS during the Int. J. Med. Sci. 2010, 7 
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progression of their disease. 
Daily activities and lifestyle in our study patients 
MS is a debilitating disease and the concurrent 
diagnosis of POTS in our study population has re-
sulted in substantial limitation of daily activities. 
POTS can have tremendous effect on the quality of life 
often resulting in severe limitation of daily activities; 
in addition, an often neglected but nonetheless im-
portant aspect of this disorder is the tremendous so-
cial, economical and emotional toll it takes on the pa-
tients but also on their families.  
POTS, when it occurs in patients of MS can add 
to the morbidity and disability these patients are al-
ready suffering from. As seen in our patient popula-
tion recognition and management of POTS in patients 
of MS may result in improved quality of life. 
Limitations 
Our study was a single center, retrospective and 
nonrandomized descriptive analysis of a small num-
ber of patients, which predisposed it to an inherent 
selection bias. One of the major limitations of this 
study was the manner in which the patients were in-
cluded in this small study. These patients had accu-
mulated over years and had been referred from mul-
tiple centers for second opinion. Thus it was difficult 
to determine the incidence of POTS in MS patients 
based on the analysis of this small population. There 
was no age matched control group of MS patients 
without POTS. This study reviewed the subjective 
reports on the symptoms of POTS in MS patient. The 
nature of the severity of symptom improvement 
and/or worsening with medication was again subjec-
tive and not assessed by a response to HUTT. These 
limitations do not influence our conclusion that POTS 
can occur in patients with MS. 
Conclusion 
Autonomic dysfunction in the form of POTS can 
occur in MS patients.  
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